m. Most
notably, for directing the first successful bone marrow transplant in
1970 on people who were not twins.

juvenile j

Antibacterial activity and resistance development in the pre-clinical studies
suggest a unique clinical potential for treating drug-resistant infections.com for the latest news and
in-depth information about TaiGen Biotechnology.

infectious fungal

D.
Senior Vice President of Global Business Development
Tel: +886-2-2790-1861

Donnall Thomas will present the keynote
address to the American Transplant Congress 2005 (ATC 2005) at the
Washington State Convention + Trade Center in Seattle, WA.

tinea j

"

About TG-873870
TG -873870 is a bacterial topoisomerase inhibitor. He is one of
the world's key figures in identifying and understanding molecular and
genetic mechanisms contributing to triggering of autoimmune disorders .
Following Dr.

joint joubert

The product is particularly important for Asian countries where the incidence
of drug resistant infections is significantly higher than in the rest of the
world. TaiGen currently has offices in Taiwan, China and the
US for R+D, business development, clinical development and marketing
operations.

infectious jacobsen

itch joint

TAIPEI, Taiwan, June 18 /Xinhua-PRNeswire/ -- TaiGen Biotechnology Co. Please visit http://www., Dr. Media interviews are
welcomed.

musculoskeletal juvenile

In October 2004, Procter + Gamble Pharmaceuticals completed the phase1A
single-dose escalating studies. Based on favorable safety and pharmacokinetic
profiles, the double-blinded, multiple-dose escalating Phase 1B trial in
healthy volunteers will guide the selection of the dosage in Phase 2 trials
planned for the first half of 2006. Through an alliance with P+G for worldwide development, TaiGen has
established a business model for emerging Asian biotechnology companies, with
the goal of gaining access to the worldwide market while retaining commercial
participation in the region.m.

genetic joint

The multiple-dose
tolerance and safety study is being conducted at a leading clinical research
center in the United States. Congressman Inslee has worked
tirelessly to author legislation to provide grants and funding to
organ donor coordinators for hospitals and organ procurement
organizations.

musculoskeletal juvenile

Visit www.com

juvenile j

The company is developing into an integrated pharmaceutical company
and is currently developing a number of innovative new products, both
internally and by in-licensing, including drugs to treat immune disorders,
cancer and infectious diseases.
On Sunday, May 22 at 12:00 p. Nepom's Address on Sunday, May 22, Congressman Jay
Inslee will address the Congress.org for a complete meeting schedule, key
speakers, information , and meeting times.

rheumatoid j

Business Editors/Health/Medical Writers
ATC 2005

MOUNT LAUREL, N.

syndrome rare

TaiGen Initiates Phase 1B Trial of a Novel Quinolone Antibiotic with Broad-Spectrum Activity Toward Drug-Sensitive and Resistant Bacteria

TaiGen Biotechnology licensed the product for
worldwide clinical development.
These properties may distinguish TG-873870 from other members of the quinolone
class. E. Gerald Nepom will present the
State-of-the-Art Address. Since 1985, he has been Member and
Scientific Director of the Research Programs at Benaroya Research
Institute at Virginia Mason .

rheumatoid rare

His talk will review the
Evolution of Bone Marrow Transplantation.atcmeeting.

itch juvenile

Ming-Chu Hsu, President and CEO of TaiGen Biotechnology, has given the
following statement: "Based on the activity profile of TG-873870, we believe
that this antibiotic, which has a unique quinolone structure, could
potentially be effective in treating multi-drug resistant infections,
including infections of methicillin-resistant Staphylococcus aureus (MRSA).

Contact:

TaiGen Biotechnology
Stephen Ip , Ph., Dr.

health musculoskeletal

Dr.----On Tuesday, May
24 at 12:00 p. Nepom has served as the
Expert Panel Chair for the NIH on autoimmune diseases. If interested, please contact Steven Schiff at 610-449-8056
or steve@schiffmarketing.

tinea infections

taigenbiotech. Thomas was co-winner of
the 1990 Nobel Prize for his contributions to transplantation.
The ATC 2005 is the sixth annual American Transplant Congress and
is widely regarded as the world's premiere conference and meeting in
the field of basic and clinical transplantation .

fungal infectious

About TaiGen Biotechnology
TaiGen Biotechnology is a privately held pharmaceutical company based in
Taiwan. Known as
the "father of bone marrow transplant", Dr. Dr.

disorders arthritis

American Transplant Congress 2005: Nobel Prize Winner to Address Congress and Other Notable Talks

Thomas was the driving force in
establishing the Fred Hutchinson Cancer Research Center, which is now
a world leader in transplantation biology. This joint meeting is
sponsored by the American Society of Transplant Surgeons (ASTS) and
the American Society of Transplantation (AST) and will occur from May
21-25 , 2005 at the Washington State Convention + Trade Center in
Seattle, WA.

juvenile infections

Compared with currently
marketed quinolones, TG-873870 represents a novel structural series. After three years of operation , in addition
to the clinical development of TG-873870, the company has drug candidates in
pre -clinical development for tissue ischemia, transplant rejection, rheumatoid
arthritis, solid tumors and SARS, and is actively pursuing late-stage
development compounds.J.

fungal tinea

Ltd. announced today that it has initiated dosing in a Phase 1B trial for
TG-873870, a novel quinolone antibiotic with the potential for treating
drug-sensitive and drug-resistant bacterial infections. His studies focus on type I diabetes and
adult and juvenile rheumatoid arthritis. Dr. This provision was later included in the Organ Donation
+ Recovery Improvement Act, which was signed by President Bush and
enacted into law on April 5th, 2004.

syndrome fungal

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)